# Urgent Need for Clinical Trials on Cannabinoids in HR+ Breast Cancer Therapy > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoids-hormone-receptor-positive-breast-cancer/ > **Published:** 2020-12-29T14:14:25-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:17:18-04:00 > **Clinical Summary:** Explore the urgent need for clinical trials on cannabinoids hormone receptor-positive breast cancer therapy and their effects on treatment safety. --- ### Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment ​ In Summary Breast cancer (BC) is the most common cancer in women worldwide. Approximately 70-80% of BC cases fall into the category of hormone receptor-positive (HR+), which derives its name from the presence of estrogen receptors (ER) on the cancerous cells and is responsive to endocrine therapy (ET). The endocannabinoid signaling system (ECS) of the body includes naturally produced chemicals called cannabinoids, the receptors which they bind to, and the enzymes that synthesize and degrade them. Cannabinoids are most well known as the active components in the plant cannabis. Although the interaction between the ECS and the hormonal axis central to ovulation in women is well-documented, little evidence exists on the effect of cannabinoids consumption on HR+ BC treatment. Some clinical studies, however, suggest that targeted therapy drugs commonly prescribed for HR+ BC patients including tamoxifen appear to act as inhibitors of [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/). In addition, some researchers propose that activity of cannabinoids when consumed by patients can interfere with other endocrine medications commonly used in HR+ BC therapy. Documenting the safety of cannabinoid use in patients undergoing therapy for HR+ BC, therefore, is an urgent need, especially when cannabinoids are integrated frequently into palliative medicine. Until further evidence from clinical studies become available, caution should be exercised by physicians and patients when cannabinoid is consumed during therapy for HR+ BC and any other cancer. LEARN MORE [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Almost – CBD and THC Did More Than Just Affect Ovarian Cancer Cells in the Lab](https://cedclinic.com/preclinical-cancer-research-cannabinoids-cbd-thc-effects/) Explore preclinical research on how cannabinoids like CBD and THC affect cancer cells beyond ovarian cancer, providing insights relevant to breast cancer studies. [Read More](https://cedclinic.com/preclinical-cancer-research-cannabinoids-cbd-thc-effects/) [How Cannabis Is Being Used in Therapeutic Treatments – Breaking AC](https://cedclinic.com/cannabis-therapeutic-treatments-research-insights/) An overview of current therapeutic uses of cannabis, including emerging research relevant to cancer and hormone-related therapies. [Learn More](https://cedclinic.com/cannabis-therapeutic-treatments-research-insights/) [Medical Cannabis Evidence-Based Care: Endocannabinoid System Clinical Research and Cannabinoid Dosing in Family Medicine](https://cedclinic.com/prenatal-cannabis-polysubstance-use-risks/) [Clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) on the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) and cannabinoid dosing provides foundational knowledge for safe [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) use in complex conditions. [Explore Now](https://cedclinic.com/prenatal-cannabis-polysubstance-use-risks/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Urgent%20Need%20for%20Clinical%20Trials%20on%20Cannabinoids%20in%20HR%2B%20Breast%20Cancer%20Therapy&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-hormone-receptor-positive-breast-cancer%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-hormone-receptor-positive-breast-cancer%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Urgent%20Need%20for%20Clinical%20Trials%20on%20Cannabinoids%20in%20HR%2B%20Breast%20Cancer%20Therapy%20https%3A%2F%2Fcedclinic.com%2Fcannabinoids-hormone-receptor-positive-breast-cancer%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).